TY - JOUR
T1 - The VICTORY (Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions) Study: Protocol for a Cross-sectional Observational Study
AU - Fox, Lauren
AU - Gates, Jessica
AU - De Vos, Ruth
AU - Wiffen, Laura
AU - Hicks, Alexander
AU - Rupani, Hitasha
AU - Williams, Jane
AU - Brown, Thomas
AU - Chauhan, Anoop J
PY - 2021/7/9
Y1 - 2021/7/9
N2 - More than 7% of the world's population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H O ) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. We will perform a single-visit, cross-sectional observational study of EBC H O levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. The results from this study will be available in 2022, in anticipation of COVID-19-related delays. This study will investigate the EBC H O , as well as other exhaled breath parameters, for use as a future diagnostic tool. [Abstract copyright: ©Lauren Fox, Jessica Gates, Ruth De Vos, Laura Wiffen, Alexander Hicks, Hitasha Rupani, Jane Williams, Thomas Brown, Anoop J Chauhan. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 09.07.2021.]
AB - More than 7% of the world's population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H O ) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. We will perform a single-visit, cross-sectional observational study of EBC H O levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. The results from this study will be available in 2022, in anticipation of COVID-19-related delays. This study will investigate the EBC H O , as well as other exhaled breath parameters, for use as a future diagnostic tool. [Abstract copyright: ©Lauren Fox, Jessica Gates, Ruth De Vos, Laura Wiffen, Alexander Hicks, Hitasha Rupani, Jane Williams, Thomas Brown, Anoop J Chauhan. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 09.07.2021.]
KW - Asthma
KW - Breathing pattern disorder
KW - Bronchiectasis
KW - COPD
KW - Diagnosis
KW - Exhalation
KW - Hydrogen peroxide
KW - Interstitial lung disease
KW - Lung cancer
KW - Lung diseases
KW - Medical device
KW - Pneumonia
U2 - 10.2196/23831
DO - 10.2196/23831
M3 - Journal Article
C2 - 34255725
SN - 1929-0748
VL - 10
JO - JMIR Research Protocols
JF - JMIR Research Protocols
IS - 7
M1 - e23831
ER -